Anti-Diabetes Drugs segment revenues Poland 2017-2029

The revenue in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in Poland was forecast to continuously increase between 2024 and 2029 by in total 98.5 million U.S. dollars (+40.29 percent). After the twelfth consecutive increasing year, the indicator is estimated to reach 342.95 million U.S. dollars and therefore a new peak in 2029. Notably, the revenue of the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market was continuously increasing over the past years.

Find further information concerning the revenue in the pharmaceuticals market in the Dominican Republic and the revenue in the pharmaceuticals market in Brazil.

The Statista Market Insights cover a broad range of additional markets.

Revenue in the Anti-Diabetes Drugs segment in Poland from 2017 to 2029 (in million U.S. dollars)

Characteristic	In million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Citation formats